picolinic acid has been researched along with Obesity in 20 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study tested the hypothesis that supplementation of chromium picolinate (CrPic), 200 microg Cr/d, compared with an equivalent amount of picolinic acid (1720 microg) in CrPic and placebo, decreases body weight, alters body composition, and reduces iron status of women fed diets of constant energy and nutrients." | 9.12 | Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. ( Lukaski, HC; Penland, JG; Siders, WA, 2007) |
| "This study tested the hypothesis that supplementation of chromium picolinate (CrPic), 200 microg Cr/d, compared with an equivalent amount of picolinic acid (1720 microg) in CrPic and placebo, decreases body weight, alters body composition, and reduces iron status of women fed diets of constant energy and nutrients." | 5.12 | Chromium picolinate supplementation in women: effects on body weight, composition, and iron status. ( Lukaski, HC; Penland, JG; Siders, WA, 2007) |
| "Chromium treatment has been reported to improve glycemic control and insulin sensitivity in specific populations of patients with type 2 diabetes." | 2.72 | Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. ( Bakker, SJ; Bilo, HJ; Gans, RO; Groenier, KH; Houweling, ST; Jansman, FG; Kleefstra, N; Meyboom-de Jong, B, 2006) |
| "Body weight was measured as BMI and body composition after calculation from skinfold thickness." | 2.68 | [Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet]. ( Bahadori, B; Schneider, H; Toplak, H; Wallner, S; Wascher, TC, 1997) |
| "Obesity is a global public health threat." | 2.49 | Chromium picolinate supplementation for overweight or obese adults. ( Ge, S; Guo, X; He, Z; Sun, R; Tian, H; Wang, X; Zhang, Z, 2013) |
| "Overweight or obesity is strongly associated with comorbidities such as type 2 diabetes mellitus, hypertension, heart disease, gall bladder disease, and sleep apnea." | 2.41 | A functional food product for the management of weight. ( Bell, SJ; Goodrick, GK, 2002) |
| "Obesity is a prevalent disorder characterized as marked insulin resistance and low grade inflammation." | 1.37 | Submandibular gland and caries susceptibility in the obese Zucker rat. ( Abdelsayed, R; El-Marakby, A; El-Salanty, M; Liu, JY; Mozaffari, MS; Wimborne, H; Zakhary, I, 2011) |
| "To evaluate whether CrPic may aid in treatment of the insulin resistance syndrome, we assessed its effects in JCR:LA-corpulent rats, a model of this syndrome." | 1.31 | Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. ( Baldor, LC; Cefalu, WT; Russell, JC; Wang, ZQ; Zhang, XH, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 4 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, H | 1 |
| Guo, X | 1 |
| Wang, X | 1 |
| He, Z | 1 |
| Sun, R | 1 |
| Ge, S | 1 |
| Zhang, Z | 1 |
| Zhou, J | 1 |
| Xu, H | 1 |
| Huang, K | 1 |
| Iqbal, N | 1 |
| Cardillo, S | 1 |
| Volger, S | 1 |
| Bloedon, LT | 1 |
| Anderson, RA | 3 |
| Boston, R | 1 |
| Szapary, PO | 1 |
| Mozaffari, MS | 1 |
| Abdelsayed, R | 1 |
| Zakhary, I | 1 |
| El-Salanty, M | 1 |
| Liu, JY | 1 |
| Wimborne, H | 1 |
| El-Marakby, A | 1 |
| Bell, SJ | 2 |
| Van Ausdal, W | 1 |
| Grochoski, G | 1 |
| Sahin, N | 1 |
| Akdemir, F | 1 |
| Orhan, C | 1 |
| Aslan, A | 1 |
| Agca, CA | 1 |
| Gencoglu, H | 1 |
| Ulas, M | 1 |
| Tuzcu, M | 1 |
| Viyaja, J | 1 |
| Komorowskı, JR | 1 |
| Sahin, K | 1 |
| Campbell, WW | 2 |
| Joseph, LJ | 1 |
| Davey, SL | 1 |
| Hinton, J | 1 |
| Evans, WJ | 1 |
| Pittler, MH | 1 |
| Stevinson, C | 1 |
| Ernst, E | 1 |
| Wang, ZQ | 2 |
| Zhang, XH | 2 |
| Russell, JC | 2 |
| Hulver, M | 1 |
| Cefalu, WT | 2 |
| Kleefstra, N | 1 |
| Houweling, ST | 1 |
| Jansman, FG | 1 |
| Groenier, KH | 1 |
| Gans, RO | 1 |
| Meyboom-de Jong, B | 1 |
| Bakker, SJ | 1 |
| Bilo, HJ | 1 |
| Lydic, ML | 1 |
| McNurlan, M | 1 |
| Bembo, S | 1 |
| Mitchell, L | 1 |
| Komaroff, E | 1 |
| Gelato, M | 1 |
| Lukaski, HC | 1 |
| Siders, WA | 1 |
| Penland, JG | 1 |
| Diaz, ML | 1 |
| Watkins, BA | 1 |
| Li, Y | 1 |
| Trent, LK | 1 |
| Thieding-Cancel, D | 1 |
| Grant, KE | 1 |
| Chandler, RM | 1 |
| Castle, AL | 1 |
| Ivy, JL | 1 |
| Bahadori, B | 1 |
| Wallner, S | 1 |
| Schneider, H | 1 |
| Wascher, TC | 1 |
| Toplak, H | 1 |
| Kato, I | 1 |
| Vogelman, JH | 1 |
| Dilman, V | 1 |
| Karkoszka, J | 1 |
| Frenkel, K | 1 |
| Durr, NP | 1 |
| Orentreich, N | 1 |
| Toniolo, P | 1 |
| Cohn, LA | 1 |
| Dodam, JR | 1 |
| McCaw, DL | 1 |
| Tate, DJ | 1 |
| Goodrick, GK | 1 |
| Baldor, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Randomized Controlled Clinical Trial of Chromium Picolinate on Clinical and Biochemical Features of the Metabolic Syndrome[NCT00128154] | 60 participants | Interventional | 2004-01-31 | Completed | |||
| Effect of Chromium Supplementation on Insulin Sensitivity in Patients With Type 2 Diabetes[NCT01368328] | Phase 3 | 57 participants (Anticipated) | Interventional | 2010-03-31 | Active, not recruiting | ||
| Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-blinded and Placebo-controlled Trial[NCT02529046] | 28 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for picolinic acid and Obesity
| Article | Year |
|---|---|
Chromium picolinate supplementation for overweight or obese adults.
Topics: Adult; Dietary Supplements; Humans; Obesity; Overweight; Picolinic Acids; Randomized Controlled Tria | 2013 |
Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azoles; Chromium Compounds; Cysteine; Diabetes Mellitus, Ty | 2016 |
Do dietary supplements help promote weight loss?
Topics: Citrates; Dietary Supplements; Humans; Lactones; Micronutrients; Obesity; Orlistat; Phytotherapy; Pi | 2009 |
Chromium picolinate for reducing body weight: meta-analysis of randomized trials.
Topics: Dietary Supplements; Female; Humans; Iron Chelating Agents; Male; Obesity; Picolinic Acids; Randomiz | 2003 |
A functional food product for the management of weight.
Topics: 5-Hydroxytryptophan; Anti-Obesity Agents; Appetite; Chromium; Dietary Carbohydrates; Dietary Fiber; | 2002 |
9 trials available for picolinic acid and Obesity
| Article | Year |
|---|---|
Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults.
Topics: Academic Medical Centers; Adult; Aged; Blood Glucose; C-Reactive Protein; Double-Blind Method; Femal | 2009 |
Effects of resistive training and chromium picolinate on body composition and skeletal muscle size in older women.
Topics: Aged; Analysis of Variance; Body Composition; Double-Blind Method; Female; Humans; Iron Chelating Ag | 2002 |
Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Blood Pressure; Body Mass Index; Chromium; Diabetes Mellitus, Type 2; Double-Blind Method; Fem | 2006 |
Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Insulin Resistance; Iron Chelating Agents; Obesity; Picolini | 2006 |
Chromium picolinate supplementation in women: effects on body weight, composition, and iron status.
Topics: Absorptiometry, Photon; Adult; Anthropometry; Biomarkers; Body Composition; Body Weight; Chromium; D | 2007 |
Chromium picolinate and conjugated linoleic acid do not synergistically influence diet- and exercise-induced changes in body composition and health indexes in overweight women.
Topics: Adult; Blood Glucose; Blood Pressure; Body Composition; Caloric Restriction; Diet; Dietary Supplemen | 2008 |
Effects of chromium picolinate on body composition.
Topics: Adult; Body Composition; Double-Blind Method; Female; Humans; Iron Chelating Agents; Male; Military | 1995 |
[Effect of chromium yeast and chromium picolinate on body composition of obese, non-diabetic patients during and after a formula diet].
Topics: Adult; Body Composition; Body Mass Index; Body Weight; Chromium; Diet, Reducing; Double-Blind Method | 1997 |
Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil.
Topics: Analysis of Variance; Antibody Formation; Confidence Intervals; Dietary Supplements; DNA Damage; Fem | 1998 |
6 other studies available for picolinic acid and Obesity
| Article | Year |
|---|---|
Submandibular gland and caries susceptibility in the obese Zucker rat.
Topics: Animals; Dental Caries; Dental Caries Susceptibility; Dietary Supplements; Inflammation Mediators; I | 2011 |
A novel nutritional supplement containing chromium picolinate, phosphatidylserine, docosahexaenoic acid, and boron activates the antioxidant pathway Nrf2/HO-1 and protects the brain against oxidative stress in high-fat-fed rats.
Topics: Aldehydes; Animals; Antioxidants; Boron; Brain; C-Reactive Protein; Cysteine Proteinase Inhibitors; | 2012 |
Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats.
Topics: Animals; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Muscle, Sk | 2006 |
Chromium and exercise training: effect on obese women.
Topics: Adolescent; Adult; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Exercise Therapy; Fem | 1997 |
Effects of chromium supplementation on glucose tolerance in obese and nonobese cats.
Topics: Animals; Blood Glucose; Cat Diseases; Cats; Dietary Supplements; Female; Glucose Tolerance Test; Ins | 1999 |
Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats.
Topics: Administration, Oral; Animals; Area Under Curve; Blood Glucose; Carbohydrate Metabolism; Diabetes Me | 2002 |